Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada

BACKGROUND: In Canada, epidermal growth factor receptor (EGFR) inhibitor therapies in advanced non-small cell lung cancer (NSCLC) were initially approved regardless of EGFR status. The purpose of this study is to characterise the use of second or later-line erlotinib therapy in Ontario, Canada from...

Descripción completa

Detalles Bibliográficos
Autores principales: Perdrizet, Kirstin, Sutradhar, Rinku, Li, Qing, Liu, Ning, Earle, Craig C., Leighl, Natasha B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482335/
https://www.ncbi.nlm.nih.gov/pubmed/34659808
http://dx.doi.org/10.21037/jtd-21-804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482335/
https://www.ncbi.nlm.nih.gov/pubmed/34659808
http://dx.doi.org/10.21037/jtd-21-804

Ejemplares similares